{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-128598","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.835654+00:00","generated_at":"2026-06-07T07:48:26.437989+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS initiates arbitration against 3D Medicines over $13M milestone payments and GPS development in China","bullets":["Dispute over $13M development milestone payments due under 2020 license agreement for GPS in China region.","3D Medicines enrolled patients in Taiwan but failed to begin mainland China enrollment as expected in H2 2023.","SELLAS claims 3D Medicines failed to use commercially reasonable best efforts; arbitration filed at HKIAC under NY law.","Company cannot predict arbitration outcome or timing of any milestone payments or damages."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-128598","json":"https://secwatch.observer/filing/0001104659-23-128598.json","markdown":"https://secwatch.observer/filing/0001104659-23-128598.md","text":"https://secwatch.observer/filing/0001104659-23-128598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923128598/0001104659-23-128598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923128598/tm2333390d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:48:26.437989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}